Evidence map›Paper›PMID 25192072›Full record

ArticleJournal of aerosol medicine and pulmonary drug delivery2015

Efficient Nose-to-Lung (N2L) Aerosol Delivery with a Dry Powder Inhaler.

P Worth Longest, Laleh Golshahi, Srinivas R B Behara, Geng Tian, Dale R Farkas, Michael Hindle

Open access · greenAbstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of aerosol medicine and pulmonary drug delivery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

P Worth Longest1Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, Virginia.
Laleh Golshahi1Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, Virginia.
Srinivas R B Behara1Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, Virginia.
Geng Tian1Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, Virginia.
Dale R Farkas1Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, Virginia.
Michael Hindle2Department of Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia.
Virginia Commonwealth University · US

Funding

High Efficiency Aerosol Delivery using the Excipient Enhanced Growth Concept: A Human Proof of Concept StudyR01HL107333 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI HINDLE, MICHAEL, LONGEST, P. WORTH · 2011 to 2020
$4.2M
NHLBI NIH HHS R01 HL107333
6 · The paper itself

Abstract

purposeDelivering aerosols to the lungs through the nasal route has a number of advantages, but its use has been limited by high depositional loss in the extrathoracic airways. The objective of this study was to evaluate the nose-to-lung (N2L) delivery of excipient enhanced growth (EEG) formulation aerosols generated with a new inline dry powder inhaler (DPI). The device was also adapted to enable aerosol delivery to a patient simultaneously receiving respiratory support from high flow nasal cannula (HFNC) therapy.

methodsThe inhaler delivered the antibiotic ciprofloxacin, which was formulated as submicrometer combination particles containing a hygroscopic excipient prepared by spray-drying. Nose-to-lung delivery was assessed using in vitro and computational fluid dynamics (CFD) methods in an airway model that continued through the upper tracheobronchial region.

resultsThe best performing device contained a 2.3 mm flow control orifice and a 3D rod array with a 3-4-3 rod pattern. Based on in vitro experiments, the emitted dose from the streamlined nasal cannula had a fine particle fraction <5 μm of 95.9% and mass median aerodynamic diameter of 1.4 μm, which was considered ideal for nose-to-lung EEG delivery. With the 2.3-343 device, condensational growth in the airways increased the aerosol size to 2.5-2.7 μm and extrathoracic deposition was <10%. CFD results closely matched the in vitro experiments and predicted that nasal deposition was <2%.

conclusionsThe developed DPI produced high efficiency aerosolization with significant size increase of the aerosol within the airways that can be used to enable nose-to-lung delivery and aerosol administration during HFNC therapy.

Indexed as

Dry Powder InhalersAdministration, IntranasalAerosolsAnti-Bacterial AgentsCatheterizationCathetersChemistry, PharmaceuticalCiprofloxacinComputer SimulationEquipment DesignExcipientsHumansLungModels, AnatomicNoninvasive VentilationNoseAerosolsAnti-Bacterial AgentsCiprofloxacinExcipientsPowdersactive dry powder inhaler (DPI) systemenhanced condensational growth (ECG)excipient enhanced growth (EEG)high flow nasal cannula (HFNC)noninvasive ventilation (NIV)

Identifiers

PMID25192072
PMCPMC4559155
OpenAlexW1510454481

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.